» Articles » PMID: 37152710

A New Osteogenic Protein Isolated from Thunb Accelerates Bone Defect Healing Through the MTOR Signaling Axis

Overview
Journal Bioact Mater
Date 2023 May 8
PMID 37152710
Authors
Affiliations
Soon will be listed here.
Abstract

Delayed bone defect repairs lead to severe health and socioeconomic impacts on patients. Hence, there are increasing demands for medical interventions to promote bone defect healing. Recombinant proteins such as BMP-2 have been recognized as one of the powerful osteogenic substances that promote mesenchymal stem cells (MSCs) to osteoblast differentiation and are widely applied clinically for bone defect repairs. However, recent reports show that BMP-2 treatment has been associated with clinical adverse side effects such as ectopic bone formation, osteolysis and stimulation of inflammation. Here, we have identified one new osteogenic protein, named 'HKUOT-S2' protein, from Thunb Using the bone defect model, we have shown that the HKUOT-S2 protein can accelerate bone defect repair by activating the mTOR signaling axis of MSCs-derived osteoblasts and increasing osteoblastic biomineralization. The HKUOT-S2 protein can also modulate the transcriptomic changes of macrophages, stem cells, and osteoblasts, thereby enhancing the crosstalk between the polarized macrophages and MSCs-osteoblast differentiation to facilitate osteogenesis. Furthermore, this protein had no toxic effects . We have also identified HKUOT-S2 peptide sequence TKSSLPGQTK as a functional osteogenic unit that can promote osteoblast differentiation . The HKUOT-S2 protein with robust osteogenic activity could be a potential alternative osteoanabolic agent for promoting osteogenesis and bone defect repairs. We believe that the HKUOT-S2 protein may potentially be applied clinically as a new class of osteogenic agent for bone defect healing.

Citing Articles

Research progress of gene therapy combined with tissue engineering to promote bone regeneration.

Chu X, Xiong Y, Lu L, Wang Y, Wang J, Zeng R APL Bioeng. 2024; 8(3):031502.

PMID: 39301183 PMC: 11412735. DOI: 10.1063/5.0200551.


Low-molecular-weight estrogenic phytoprotein suppresses osteoporosis development through positive modulation of skeletal estrogen receptors.

Kubi J, Brah A, Cheung K, Chen A, Lee Y, Lee K Bioact Mater. 2024; 42:299-315.

PMID: 39290337 PMC: 11405634. DOI: 10.1016/j.bioactmat.2024.08.045.

References
1.
Tieppo Francio V, Davani S, Towery C, Brown T . Oral Versus Topical Diclofenac Sodium in the Treatment of Osteoarthritis. J Pain Palliat Care Pharmacother. 2017; 31(2):113-120. DOI: 10.1080/15360288.2017.1301616. View

2.
Lafuente-Gracia L, Borgiani E, Nasello G, Geris L . Towards Models of the Inflammatory Response in Bone Fracture Healing. Front Bioeng Biotechnol. 2021; 9:703725. PMC: 8514728. DOI: 10.3389/fbioe.2021.703725. View

3.
Shin R, Lee C, Shen O, Xu H, Lee O . The Crosstalk between Mesenchymal Stem Cells and Macrophages in Bone Regeneration: A Systematic Review. Stem Cells Int. 2021; 2021:8835156. PMC: 8219422. DOI: 10.1155/2021/8835156. View

4.
Kumar S, Das G, Shin H, Patra J . spp. (A Wild Edible Tuber): A Study on Its Ethnopharmacological Potential and Traditional Use by the Local People of Similipal Biosphere Reserve, India. Front Pharmacol. 2017; 8:52. PMC: 5306286. DOI: 10.3389/fphar.2017.00052. View

5.
Chen J, Holguin N, Shi Y, Silva M, Long F . mTORC2 signaling promotes skeletal growth and bone formation in mice. J Bone Miner Res. 2014; 30(2):369-78. PMC: 4322759. DOI: 10.1002/jbmr.2348. View